



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
<https://www.wjgnet.com>

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 88021

**Title:** Evaluation of the effect of bevacizumab combined with XELOX on patients with advanced colorectal cancer by detecting serum tumor markers CEA, C 25 and C 99

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06540810

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Associate Specialist, Doctor, Research Associate

**Reviewer's Country/Territory:** Spain

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-10-30

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-11-01 07:53

**Reviewer performed review:** 2023-11-07 09:55

**Review time:** 6 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The treatment of mCRC is generally based on XELOX in clinical practice, which includes capecitabine and oxaliplatin. However, after XELOX treatment, subsequent maintenance therapy usually uses low-intensity and low-toxicity drugs. Bevacizumab, a monoclonal antibody with targeted effects, can inhibit tumor growth and metastasis by inhibiting the formation of tumor neovascularization caused by the binding of VEGF to its receptor. This study explored the efficacy and prognosis of BEV combined with XELOX adjuvant chemotherapy in patients with advanced mCRC by detection of serum levels of CEA, CA199 and CA125. Overall, this study is well performed, the findings are very interesting. After a minor revision, it can be accepted. Comments: 1. Please edit the manuscript carefully. The aim of the study should be removed from the background of the abstract, and add it under a subtitle of "Aim". 2. Please define the abbreviations when they first appear in the text. 3. Please make a short discuss about the limit of the study. 4. Please update the references.